PURPOSE: To study pre-treatment serum VEGF of patients with invasive cervical cancer and its possible role as prognostic indicator. METHODS: VEGF was measured using ELISA in the largest patient group (n = 167) to date. RESULTS: Serum VEGF was significantly higher in advanced tumor stage (P = 0.01), large tumor size (tumors larger than 2 cm) (P = 0.03), and the presence of vascular space invasion (P = 0.05). Serum VEGF was associated with disease free and overall survival [DFS: Hazard Ratio (HR) = 2.61; 95% CI 1.32-5.17; P = 0.006; for OS: HR = 2.09; 95% CI 1.54-2.84; P < 0.001, respectively]. In multivariate Cox regression serum VEGF retained its prognostic value for DFS (HR = 2.10, P = 0.03) and OS (HR = 1.92, P = 0.04). CONCLUSIONS: Serum VEGF levels correlate with more advanced and more aggressive disease in cervical cancer and may be a useful prognostic factor in patients with cervical cancer.
PURPOSE: To study pre-treatment serum VEGF of patients with invasive cervical cancer and its possible role as prognostic indicator. METHODS:VEGF was measured using ELISA in the largest patient group (n = 167) to date. RESULTS: Serum VEGF was significantly higher in advanced tumor stage (P = 0.01), large tumor size (tumors larger than 2 cm) (P = 0.03), and the presence of vascular space invasion (P = 0.05). Serum VEGF was associated with disease free and overall survival [DFS: Hazard Ratio (HR) = 2.61; 95% CI 1.32-5.17; P = 0.006; for OS: HR = 2.09; 95% CI 1.54-2.84; P < 0.001, respectively]. In multivariate Cox regression serum VEGF retained its prognostic value for DFS (HR = 2.10, P = 0.03) and OS (HR = 1.92, P = 0.04). CONCLUSIONS: Serum VEGF levels correlate with more advanced and more aggressive disease in cervical cancer and may be a useful prognostic factor in patients with cervical cancer.
Authors: T Kaku; T Hirakawa; T Kamura; S Amada; N Kinukawa; H Kobayashi; K Sakai; K Ariyoshi; K Sonoda; H Nakano Journal: Cancer Date: 1998-10-01 Impact factor: 6.860
Authors: D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed Journal: Cell Date: 1998-09-18 Impact factor: 41.582
Authors: Pedro Villarejo-Campos; David Padilla-Valverde; Raúl Martin Martin; Pablo Menéndez-Sánchez; Teófilo Cubo-Cintas; Jose Antonio Bondia-Navarro; Jesús Martín Fernández Journal: Clin Transl Oncol Date: 2012-07-24 Impact factor: 3.405
Authors: Chantal van de Schootbrugge; Johan Bussink; Paul N Span; Fred C G J Sweep; Reidar Grénman; Hanneke Stegeman; Ger J M Pruijn; Johannes H A M Kaanders; Wilbert C Boelens Journal: BMC Cancer Date: 2013-03-18 Impact factor: 4.430
Authors: Christine How; Angela B Y Hui; Nehad M Alajez; Wei Shi; Paul C Boutros; Blaise A Clarke; Rui Yan; Melania Pintilie; Anthony Fyles; David W Hedley; Richard P Hill; Michael Milosevic; Fei-Fei Liu Journal: PLoS One Date: 2013-07-04 Impact factor: 3.240
Authors: Karin Abbink; Petra L M Zusterzeel; Anneke Geurts-Moespot; Rob van der Steen; Paul N Span; Fred C G J Sweep Journal: J Cancer Res Clin Oncol Date: 2020-05-11 Impact factor: 4.553